Federal Status
Medical cannabis is now Schedule III, here’s what that means for you
In April 2026, the federal government moved medical cannabis from Schedule I, the same category as heroin, with “no accepted medical use”, to Schedule III, which recognizes accepted medical value and a lower potential for abuse. For licensed medicinal patients and operators like ThrivePath, this is the most significant federal shift in cannabis history. Here is what it actually means in plain terms. For the full plain-language breakdown, read our Schedule III guide.
Update, July 2026: Expedited federal hearings on broader rescheduling questions began in late June 2026. Nothing changes for patients while the process runs; we track every development and explain what matters in our 2026 rescheduling hearings guide.
Update, October 2026: California's Department of Cannabis Control has proposed making permanent the rules that allow dual-licensed retailers to separate into a standalone adult-use license and a new medicinal-only license, the structure that supports federal DEA registration. Public comment is open through December 14, 2026. We cover the details in our Schedule III guide.
Update, November 2026: On October 30, 2026, the DEA began issuing the first federal registrations to state-licensed medical cannabis dispensaries and published guidance for businesses that applied on time. ThrivePath applied within the federal window and is a DEA Timely Applicant (application pending, Control ID M00001668J), which allows us to operate under our state medicinal license while the DEA completes its review. Nothing changes for patients. Read the Department of Justice announcement.
Update, November 20, 2026: Two federal requirements now shape how ThrivePath operates. First, DEA guidance requires Timely Applicants to buy only from, and sell only to, DEA registrants or other Timely Applicants by November 29, 2026, so ThrivePath sources exclusively from that federally recognized supply chain. Second, federal rules treat a signed, dated physician certification as the basis for dispensing medical cannabis, so every ThrivePath patient needs a current, signed physician's recommendation. Our recommendation guide explains how to get one.
Before, Schedule I
- Classified alongside heroin, with “no accepted medical use”
- Federal research on cannabis nearly impossible
- Businesses taxed on gross revenue, not profit (IRS 280E)
- No federal recognition of medicinal legitimacy
- Banking and financial services largely refused
Now, Schedule III
- Federally recognized as having accepted medical use
- Research pathways significantly opened
- 280E tax burden no longer applies to Schedule III operators
- Medical cannabis placed alongside medications like ketamine
- Path forward for banking, insurance, and wider access
What It Means for You as a Patient
Your medicine is now federally recognized as medicine.
For years, patients using state-licensed medical cannabis existed in a legal grey zone, their state said it was legal and therapeutic, their federal government said it had no medical value. That contradiction is now resolved. Schedule III means the federal government officially acknowledges that cannabis has accepted medicinal use. Your choice to use it is validated at every level of government.
Better Products Through More Research
Real clinical research can now happen at scale.
Schedule I status blocked universities, hospitals, and pharmaceutical researchers from studying cannabis properly. The barriers weren’t just legal, funding dried up, approval processes were nearly impossible, and researchers risked their careers. Schedule III removes most of those barriers. Expect a significant acceleration in clinical trials on cannabinoid formulations, dosing, and specific conditions over the next five years.
Lower Prices Over Time
The punishing 280E tax no longer applies.
IRS Section 280E prevented cannabis businesses from deducting normal operating expenses, staff, rent, utilities, supplies, because the business was federally classified as trafficking a controlled substance. This meant effective tax rates of 70–90% in some cases, costs that got passed to patients. As a Schedule III medicinal operator, ThrivePath is no longer subject to 280E in the same way. That financial relief makes sustainable, fairly priced medicinal access more achievable.
What Hasn’t Changed, and What’s Next
This is not full legalization. But it’s the clearest path toward it.
The April 2026 ruling applies specifically to cannabis dispensed under a qualifying state medical license. Recreational cannabis remains federally Schedule I for now. A separate DEA administrative proceeding on broader rescheduling opened in June 2026 and remains unresolved. ThrivePath continues to operate in full compliance with all California DCC requirements and applicable federal rules, and will keep patients informed as the landscape evolves.
ThrivePath operates under California DCC License C12-0000654-LIC. The April 2026 federal rescheduling applies to state-licensed medical operators. This page reflects current understanding and will be updated as federal guidance develops. Nothing here constitutes legal advice.